SUZHOU, China, and ROCKVILLE, MD, December 11, 2023—Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it has released the clinical data of lisaftoclax (APG-2575), one of the company’s key drug candidates, combined with various novel therapies in patients with Read More ›

SUZHOU, China, and ROCKVILLE, MD, December 11, 2023—Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it has released the latest efficacy and safety data of lisaftoclax (APG-2575), one of the company’s key drug candidates, in patients with heavily pretreated Read More ›

SUZHOU, China, and ROCKVILLE, MD, December 11, 2023—Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it has released updated data from a US study of the company’s novel drug candidate, olverembatinib (R&D code: HQP1351), in patients with refractory chronic Read More ›

SUZHOU, China, and ROCKVILLE, MD, 17 Nov, 2023—Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases announced today that the China National Medical Products Administration (NMPA) has approved olverembatinib (HQP1351) for the treatment of adult patients with chronic-phase chronic myeloid leukemia (CML-CP) resistant Read More ›

SUZHOU, China, and ROCKVILLE, MD, November 3, 2023—Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that results from three clinical studies of lisaftoclax (APG-2575), a key candidate drug in the Company’s pipeline, have been selected for presentations at the 65th Read More ›

SUZHOU, China, and ROCKVILLE, MD, November 3, 2023—Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that results from multiple clinical studies of the company’s novel drug candidate, olverembatinib, have been selected for presentations, including two Oral Reports, at the 65th Read More ›

SUZHOU, China, and ROCKVILLE, MD, Oct 23, 2023—Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it has released the latest clinical data of its dual Bcl-2/Bcl-xL inhibitor, APG-1252 (pelcitoclax), combined with osimertinib for the treatment of patients with EGFR-mutant Read More ›

SUZHOU, China, and ROCKVILLE, MD, Oct 17, 2023—Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that the registrational Phase III study(HQP1351AG301, NCT06051409) of olverembatinib, Ascentage Pharma’s lead drug candidate, combined with chemotherapy, versus imatinib combined with chemotherapy in treatment-naïve patients Read More ›

SUZHOU, China, and ROCKVILLE, MD, Oct16, 2023—Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it has entered into a clinical collaboration with AstraZeneca Investment (China) Co., Ltd. (or “AstraZeneca”). The two companies will jointly conduct a registrational Phase III Read More ›

SUZHOU, China, and ROCKVILLE, MD, Oct 12, 2023—Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA) has approved a global pivotal registrational Phase III study designed to Read More ›